Preventing and managing aberrant drug-related behavior in primary care: Systematic review of outcomes evidence

Journal of Opioid Management

Volumn 10, Issue 2, 2014, Pages 119-134

  Argoff, Charles E ^a   Kahan, Meldon ^b   Sellers, Edward M ^c  

^a ALBANY MEDICAL COLLEGE   (United States)

^b UNIVERSITY OF TORONTO   (Canada)

^c DL Global Partners Inc   (Canada)

Author keywords

Abuse liability; Abuse deterrence; Drug abuse; Opioids; Pain management

Indexed keywords

CODEINE; DIAMORPHINE; HYDROCODONE; HYDROMORPHONE; MORPHINE; MORPHINE SULFATE PLUS NALTREXONE; OPIATE; OXYCODONE; OXYMORPHONE; TAPENTADOL; TRAMADOL;

ANALGESIA; BEHAVIOR DISORDER; DRUG ABUSE; DRUG DOSE TITRATION; DRUG FORMULATION; DRUG MISUSE; EVIDENCE BASED PRACTICE; HUMAN; MEDICATION COMPLIANCE; MEDLINE; OUTCOME ASSESSMENT; PAIN; PATIENT ASSESSMENT; PATIENT COMPLIANCE; PRACTICE GUIDELINE; PRESCRIPTION; PRIMARY MEDICAL CARE; RATING SCALE; REVIEW; RISK REDUCTION; SUBSTANCE ABUSE; SYSTEMATIC REVIEW;

ANALGESICS, OPIOID; HUMANS; MEDICATION ADHERENCE; OPIOID-RELATED DISORDERS; PAIN MEASUREMENT; PRACTICE GUIDELINES AS TOPIC; PRIMARY HEALTH CARE; RISK ASSESSMENT;

EID: 84899808410     PISSN: 15517489     EISSN: None     Source Type: Journal    
DOI: 10.5055/jom.2014.0201     Document Type: Review

References (101)

1. Results from the 2008 National Survey on Drug Use and Health: National Findings. Substance Abuse and Mental Health Services Administration, Office of Applied Studies. Available at http://www.samhsa.gov/data/NSDUH/2K8NSDUH/tabs/ Sect1peTabslto46.htm#Tab1.1B. Accessed November 21, 2013.
2. Spitz A, Moore AA, Papaleontiou M, et al.: Primary care providers' perspective on prescribing opioids to older adults with chronic non-cancer pain: A qualitative study. BMC Geriatr. 2011; 11: 35.
3. Manchikanti L, Manchukonda R, Damron KS, et al.: Does adherence monitoring reduce controlled substance abuse in chronic pain patients? Pain Physician. 2006; 9(1): 57-60. (Pubitemid 43263665)
4. Bhamb B, Brown D, Hariharan J, et al.: Survey of select practice behaviors by primary care physicians on the use of opioids for chronic pain. Curr Med Res Opin. 2006; 22(9): 1859-1865. (Pubitemid 44449242)
5. Reisfield GM, Webb FJ, Bertholf RL, et al.: Family physicians' proficiency in urine drug test interpretation. J Opioid Manag. 2007; 3(6): 333-337. (Pubitemid 351166545)
6. Canadian guideline for safe and effective use of opioids for chronic non-cancer pain. National Opioid Use Guideline Group (NOUGG). Available at http://nationalpaincentre.mcmaster.ca/opioid/. Accessed November 21, 2013.
7. Chou R, Fanciullo GJ, Fine PG, et al.: Clinical guidelines for the use of chronic opioid therapy in chronic noncancer pain. J Pain. 2009; 10(2): 113-130.
8. Manchikanti L, Abdi S, Atluri S, et al.: American Society of Interventional Pain Physicians (ASIPP) guidelines for responsible opioid prescribing in chronic non-cancer pain: Part I - Evidence assessment. Pain Physician. 2012; 15(3 suppl): S1-S66.
9. Manchikanti L, Abdi S, Atluri S, et al.: American Society of Interventional Pain Physicians (ASIPP) guidelines for responsible opioid prescribing in chronic non-cancer pain: Part 2 - Guidance. Pain Physician. 2012; 15(3 suppl): S67-S116.
10. Extended-release (ER) and long-acting (LA) opioid analgesics risk evaluation and mitigation strategy (REMS). United States Food and Drug Administration. Available at http://www.er-la-opioidrems.com/. Accessed November 21, 2013.
11. Washington State Agency Medical Directors' Group: Interagency guidelines on opioid dosing for chronic non-cancer pain: An educational aid to improve care and safety with opioid therapy. Available at http.//www.agencymeddirectors.wa. gov/Files/OpioidGdline.pdf. Accessed November 21, 2013.
12. Laws of Florida Chapter 2011-141. Florida State Legislature. Available at http//laws.flrules.org/files/Ch-2011-141.pdf. Accessed November 21, 2013.
13. Oxford Centre for Evidence-Based Medicine - Levels of Evidence: Oxford University. Available at http://www.cebm.net/index.aspx?o=1025. Accessed November 20, 2013.
14. Kahan M, Srivastava A, Wilson L, et al.: Misuse of and dependence on opioids: Study of chronic pain patients. Can Fam Physician. 2006; 52(9): 1081-1087. (Pubitemid 44553330)
15. Brown J, Setnik B, Lee K, et al.: Assessment, stratification, and monitoring of the risk for prescription opioid misuse and abuse in the primary care setting. J Opioid Manag. 2011; 7(6): 467-483.
16. Jamison RN, Serraillier J, Michna E: Assessment and treatment of abuse risk in opioid prescribing for chronic pain. Pain Res Treat. 2011; 2011: 941808.
17. Kahan M, Wilson L, Mailis-Gagnon A, et al.: Canadian guideline for safe and effective use of opioids for chronic noncancer pain: Clinical summary for family physicians. Part 2: Special populations. Can Fam Physician. 2011; 57(11): 1269-1276.
18. Larance B, Degenhardt L, Lintzeris N, et al.: Definitions related to the use of pharmaceutical opioids: Extramedical use, diversion, non-adherence and aberrant medication-related behaviours. Drug Alcohol Rev. 2011; 30(3): 236-245.
19. United States Department of Health and Human Services Substance Abuse and Mental Health Services Administration, Office of Applied Studies: Results from the 2010 National Survey on Drug Use and Health: National Findings. Available at http://www.oas.samhsa.gov/NSDUH/2k10NSDUH/2k10Results.pdf. Accessed November 21, 2013.
20. Joranson DE, Gilson AM: Drug crime is a source of abused pain medications in the United States. J Pain Symptom Manage. 2005; 30(4): 299-301. (Pubitemid 41527112)
21. Morasco BJ, Dobscha SK: Prescription medication misuse and substance use disorder in VA primary care patients with chronic pain. Gen Hosp Psychiatry. 2008; 30(2): 93-99. (Pubitemid 351248979)
22. Green TC, Grimes Serrano JM, Licari A, et al.: Women who abuse prescription opioids: Findings from the Addiction Severity Index-Multimedia Version Connect prescription opioid database. Drug Alcohol Depend. 2009; 103(1-2): 65-73.
23. Hartzler B, Donovan DM, Huang Z: Comparison of opiate-primary treatment seekers with and without alcohol use disorder. J Subst Abuse Treat. 2010; 39(2): 114-123.
24. Johnson S, MacDonald SF, Cheverie M, et al.: Prevalence and trends of non-medical opioid and other drug use histories among federal correctional inmates in methadone maintenance treatment in Canada. Drug Alcohol Depend. 2012; 124(1-2): 172-176.
25. Morasco BJ, Turk DC, Donovan DM, et al.: Risk for prescription opioid misuse among patients with a history of substance use disorder. Drug Alcohol Depend. 2013; 127(1-3): 193-199.
26. Cicero TJ, Lynskey M, Todorov A, et al.: Co-morbid pain and psychopathology in males and females admitted to treatment for opioid analgesic abuse. Pain. 2008; 139(1): 127-135.
27. Rice JB, White AG, Bimbaum HG, et al.: A model to identify patients at risk for prescription opioid abuse, dependence, and misuse. Pain Med. 2012; 13(9): 1162-1173.
28. Rieckmann T, McCarty D, Kovas A, et al.: American Indians with substance use disorders: Treatment needs and comorbid conditions. Am J Drug Alcohol Abuse. 2012; 38(5): 498-504.
29. Seal KH, Shi Y, Cohen G, et al.: Association of mental health disorders with prescription opioids and high-risk opioid use in US veterans of Iraq and Afghanistan. JAMA. 2012; 307(9): 940-947.
30. Cohen P, Chen H, Crawford TN, et al.: Personality disorders in early adolescence and the development of later substance use disorders in the general population. Drug Alcohol Depend. 2007; 88(suppl 1): S71-S84. (Pubitemid 46282353)
31. Conroy E, Degenhardt L, Mattick RP, et al.: Child maltreatment as a risk factor for opioid dependence: Comparison of family characteristics and type and severity of child maltreatment with a matched control group. Child Abuse Negl. 2009; 33(6): 343-352.
32. Ani C, Bazargan M, Hindman D, et al.: Depression symptomatology and diagnosis: Discordance between patients and physicians in primary care settings. BMC Fam Pract. 2008; 9:1.
33. Kroenke K, Spitzer RL, Williams JB, et al.: Anxiety disorders in primary care: Prevalence, impairment, comorbidity, and detection. Ann Intern Med. 2007; 146(5): 317-325. (Pubitemid 351650592)
34. Hirschfeld RM, Cass AR, Holt DC, et al.: Screening for bipolar disorder in patients treated for depression in a family medicine clinic. J Am Board Fam Pract. 2005; 18(4): 233-239. (Pubitemid 41663994)
35. Pergolizzi JV Jr, Gharibo C, Passik S, et al.: Dynamic risk factors in the misuse of opioid analgesics. J Psychosom Res. 2012; 72(6): 443-451.
36. Butler SF, Budman SH, Fernandez KC, et al.: Development and validation of the current opioid misuse measure. Pain. 2007; 130(1-2): 144-156. (Pubitemid 46843461)
37. Webster LR, Webster RM: Predicting aberrant behaviors in opioid-treated patients: Preliminary validation of the opioid risk tool. Pain Med. 2005; 6(6): 432-442. (Pubitemid 43110296)
38. Butler SF, Fernandez K, Benoit C, et al.: Validation of the revised Screener and Opioid Assessment for Patients With Pain (SOAPP-R). J Pain. 2008; 9(4): 360-372.
39. Compton PA, Wu SM, Schieffer B, et al.: Introduction of a self-report version of the Prescription Drug Use Questionnaire and relationship to medication agreement noncompliance. J Pain Symptom Manage. 2008; 36(4): 383-395.
40. Chou R, Fanciullo GJ, Fine PG, et al.: Opioids for chronic noncancer pain: Prediction and identification of aberrant drug-related behaviors: A review of the evidence for an American Pain Society and American Academy of Pain Medicine clinical practice guideline. J Pain. 2009; 10(2): 131-146.
41. Park J, Lavin R: Risk factors associated with opioid medication misuse in community-dwelling older adults with chronic pain. Clin J Pain. 2010; 26(8): 647-655.
42. Pink LR, Smith AJ, Peng PW, et al.: Intake assessment of problematic use of medications in a chronic noncancer pain clinic. Pain Res Manag. 2012; 17(4): 276-280.
43. Hariharan J, Lamb GC, Neuner JM: Long-term opioid contract use for chronic pain management in primary care practice. A five year experience. J Gen Intern Med. 2007; 22(4): 485-490. (Pubitemid 46941204)
44. Penko J, Mattson J, Miaskowski C, et al.: Do patients know they are on pain medication agreements? Results from a sample of high-risk patients on chronic opioid therapy. PainMed. 2012; 13(9): 1174-1180.
45. Butler SF, Black RA, Cassidy TA, et al.: Abuse risks and routes of administration of different prescription opioid compounds and formulations. Harm Reduct J. 2011; 8(1): 29.
46. Passik SD, Hays L, Eisner N, et al.: Psychiatric and pain characteristics of prescription drug abusers entering drug rehabilitation. J Pain Palliat Care Pharmacother. 2006; 20(2): 5-13. (Pubitemid 43962738)
47. Kahan M, Mailis-Gagnon A, Wilson L, et al.: Canadian guideline for safe and effective use of opioids for chronic noncancer pain: Clinical summary for family physicians. Part 1: General population. Can Fam Physician. 2011; 57(11): 1257-1266, e1407-e1418.
48. Naliboff BD, Wu SM, Schieffer B, et al.: A randomized trial of 2 prescription strategies for opioid treatment of chronic nonmalignant pain. J Pain. 2011; 12(2): 288-296.
49. National Opioid Use Guideline Group: Canadian guidelines for safe and effective use of opioids for chronic non-cancer pain. McMaster University. Available at http://nationalpaincentre.mcmaster.ca/opioid/. Accessed November 21, 2013.
50. Online opioid calculator. Available at http:// opioidcalculatorpracticalpainmanagement.com/. Accessed November 21, 2013.
51. New York Langone Medical Center: GlobalRPh. Available at http://www.globalrph.com/narcoticonv.htm. Accessed November 21, 2013.
52. Johns Hopkins Center for Cancer Pain Research opioid conversion program: Available at http://www.hopweb.org/index.cfm?cfid=4634198&cftoken=46515837. Accessed November 21, 2013.
53. Bohnert AS, Valenstein M, Bair MJ, et al.: Association between opioid prescribing patterns and opioid overdose-related deaths. JAMA. 2011; 305(13): 1315-1321.
54. Dunn KM, Saunders KW, Rutter CM, et al.: Opioid prescriptions for chronic pain and overdose: A cohort study. Ann Intern Med. 2010; 152(2): 85-92.
55. Gomes T, Mamdani MM, Dhalla LA, et al.: Opioid dose and drug-related mortality in patients with nonmalignant pain. Arch Intern Med. 2011; 171(7): 686-691.
56. Gomes T, Juurlink DN, Dhalla IA, et al.: Trends in opioid use and dosing among socio-economically disadvantaged patients. Open Med. 2011; 5(1): e13-e22.
57. Franklin GM, Mai J, Turner J, et al.: Bending the prescription opioid dosing and mortality curves: Impact of the Washington State opioid dosing guideline. Am J Ind Med. 2012; 55(4): 325-331.
58. Butler SF, Benoit C, Budman SH, et al.: Development and validation of an Opioid Attractiveness Scale: A novel measure of the attractiveness of opioid products to potential abusers. Harm Reduct J. 2006; 3: 5.
59. Romach MK, Schoedel KA, Sellers EM: Update on tamper-resistant drug formulations. Drug Alcohol Depend. 2013; 130(1-3): 13-23.
60. Black R, Coplan P, Cassidy T, et al.: Effects of reformulated OxyContin® among patients assessed for substance abuse treatment in the NAVIPPRO sentinal surveillance network. J Pain. 2012; 13(4S): S58.
61. Bartholomäus J, Arkenau-Maric E, Galia E: Opioid extended-release tablets with improved tamper-resistant properties. Expert Opin Drug Deliv. 2012; 9(8): 879-891.
62. Pfizer Inc, Acura Pharmaceuticals Inc.: Pfizer and Acura Announce FDA Approval of Oxectatm (Oxycodone HCL, USP) CII [press release]. Available at http://www.pfizer.com/news/press-release/press-release-archive-detail/ pfizer-and-acura-announce-fda-approval-of-oxectatm-oxycodone-hcl-usp-cii. Accessed June 26, 2012.
63. Katz N, Sun S, Johnson F, et al.: ALO-01 (morphine sulfate and naltrexone hydrochloride) extended-release capsules in the treatment of chronic pain of osteoarthritis of the hip or knee: Pharmacokinetics, efficacy, and safety. JPain. 2010; 11(4): 303-311.
64. Webster LR, Johnson FK, Stauffer J, et al.: Impact of intravenous naltrexone on intravenous morphine-induced high, drug liking, and euphoric effects in experienced, nondependent male opioid users. Drugs RD. 2011; 11(3): 259-275.
65. Stauffer J, Setnik B, Sokolowska M, et al.: Subjective effects and safety of whole and tampered morphine sulfate and naltrexone hydrochloride (ALO-01) extended-release capsules versus morphine solution and placebo in experienced nondependent opioid users: A randomized, double-blind, placebo-controlled, crossover study. Clin Drug Investig. 2009; 29(12): 777-790.
66. thepharmaletter.com: Stability problems see Pfizer recall pain drug Embeda acquired in King deal. Available at http://www.thepharmaletter.com/file/ 102899/stability-problems-see-pfizer-recall-pain-drug-embeda-acquired-in-king- deal.html. Accessed November 21, 2013.
67. Webster LR, Bath B, Medve RA, et al.: Randomized, double-blind, placebo-controlled study of the abuse potential of different formulations of oral oxycodone. PainMed. 2012; 13(6): 790-801.
68. Butler SF, Cassidy TA, Chilcoat H, et al.: Abuse rates and routes of administration of reformulated extended-release oxycodone: Initial findings from a sentinel surveillance sample of individuals assessed for substance abuse treatment. J Pain. 2013; 14(4): 351-358.
69. Setnik B, Roland CL, Cleveland JM, et al.: The abuse potential of Remoxy®, an extended-release formulation of oxycodone, compared with immediate- and extended-release oxycodone. Pain Med. 2011; 12(4): 618-631.
70. Cicero TJ, Ellis MS, Surratt HL: Effect of abuse-deterrent formulation of OxyContin. N Engl J Med. 2012; 367(2): 187-189.
71. Vosburg SK, Jones JD, Manubay JM, et al.: Assessment of a formulation designed to be crush-resistant in prescription opioid abusers. Drug Alcohol Depend. 2012; 126(1-2): 206-215.
72. Schoedel KA, Rolleri RL, Faulknor JY, et al.: Assessing subjective and physiologic effects following intranasal administration of a new formulation of immediate release oxycodone HCl (Oxecta) tablets in nondependent recreational opioid users. J Opioid Manag. 2012; 8(5): 315-327.
73. Tompkins DA, Lanier RK, Harrison JA, et al.: Human abuse liability assessment of oxycodone combined with ultra-low-dose naltrexone. Psychopharmacology (Berl). 2010; 210(4): 471-480.
74. Cone EJ, Caplan YH, Black DL, et al.: Urine drug testing of chronic pain patients: licit and illicit drug patterns. J Anal Toxicol. 2008; 32(8): 530-543.
75. Robinson-Papp J, Elliott K, Simpson DM, et al.: Problematic prescription opioid use in an HIV-infected cohort: The importance of universal toxicology testing. J Acquir Immune Defic Syndr. 2012; 61(2): 187-193.
76. Couto JE, Webster L, Romney MC, et al.: Use of an algorithm applied to urine drug screening to assess adherence to a hydrocodone regimen. J Clin Pharm Ther. 2011; 36(2): 200-207.
77. Larson ME, Richards TM: Quantification of a methadone metabolite (EDDP) in urine: Assessment of compliance. Clin Med Res. 2009; 7(4): 134-141.
78. Manchikanti L, Malla Y, Wargo BW, et al.: Comparative evaluation of the accuracy of immunoassay with liquid chromatography tandem mass spectrometry (LC/MS/MS) of urine drug testing (UDT) opioids and illicit drugs in chronic pain patients. Pain Physician. 2011; 14(2): 175-187.
79. Starrels JL, Becker WC, Alford DP, et al.: Systematic review: Treatment agreements and urine drug testing to reduce opioid misuse in patients with chronic pain. Ann Intern Med. 2010; 152(11): 712-720.
80. Starrels JL, Fox AD, Kunins HV, et al.: They don't know what they don't know: Internal medicine residents' knowledge and confidence in urine drug test interpretation for patients with chronic pain. J Gen Intern Med. 2012; 27(11): 1521-1527.
81. Peppin JF, Passik SD, Couto JE, et al.: Recommendations for urine drug monitoring as a component of opioid therapy in the treatment of chronic pain. Pain Med. 2012; 13(7): 886-896.
82. United States General Accounting Office: State monitoring programs may help to reduce illegal diversion. Available at http://www.gao.gov/products/GAO- 04-524T. Accessed November 21, 2013.
83. Green TC, Mann MR, Bowman SE, et al.: How does use of a prescription monitoring program change medical practice? Pain Med. 2012; 13(10): 1314-1323.
84. Reifler LM, Droz D, Bailey JE, et al.: Do prescription monitoring programs impact state trends in opioid abuse/misuse? Pain Med. 2012; 13(3): 434-442.
85. Lum PJ, Little S, Botsko M, et al.: Opioid-prescribing practices and provider confidence recognizing opioid analgesic abuse in HIV primary care settings. J Acquir Immune Defic Syndr. 2011; 56(suppl 1): S91-S97.
86. Argoff CE, Wilson L, Kahan MM: Managing aberrant drug behavior in primary care. Paper presented at the International Conference on Opioids, Boston, MA, June 10-14, 2012.
87. Meghani SH, Wiedemer NL, Becker WC, et al.: Predictors of resolution of aberrant drug behavior in chronic pain patients treated in a structured opioid risk management program. Pain Med. 2009; 10(5): 858-865.
88. Peng P, Tumber P, Stafford M, et al.: Experience of methadone therapy in 100 consecutive chronic pain patients in a multidisciplinary pain center. Pain Med. 2008; 9(7): 786-794.
89. Mattick RP, Breen C, Kimber J, et al.: Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence. Cochrane Database Syst Rev. 2009; (3): CD002209.
90. Shields LB, Hunsaker Iii JC, Corey TS, et al.: Methadone toxicity fatalities: A review of medical examiner cases in a large metropolitan area. J Forensic Sci. 2007; 52(6): 1389-1395. (Pubitemid 350243438)
91. Jones JD, Sullivan MA, Manubay J, et al.: The subjective, reinforcing, and analgesic effects of oxycodone in patients with chronic, non-malignant pain who are maintained on sublingual buprenorphine/naloxone. Neuropsychopharmacology. 2011; 36(2): 411-422.
92. Blondell RD, Ashrafioun L, Dambra CM, et al.: A clinical trial comparing tapering doses of buprenorphine with steady doses for chronic pain and co-existent opioid addiction. J Addict Med. 2010; 4(3): 140-146.
93. Comer SD, Sullivan MA, Vosburg SK, et al.: Abuse liability of intravenous buprenorphine/naloxone and buprenorphine alone in buprenorphine-maintained intravenous heroin abusers. Addiction. 2010; 105(4): 709-718.
94. Alho H, Sinclair D, Vuori E, et al.: Abuse liability of buprenorphine-naloxone tablets in untreated IV drug users. Drug Alcohol Depend. 2007; 88(1): 75-78. (Pubitemid 46400304)
95. Cicero TJ, Surratt HL, Inciardi J: Use and misuse of buprenorphine in the management of opioid addiction. J Opioid Manag. 2007; 3(6): 302-308. (Pubitemid 351166541)
96. Fiellin DA, Weiss L, Botsko M, et al.: Drug treatment outcomes among HIV-infected opioid-dependent patients receiving buprenorphine/naloxone. J Acquir Immune Defic Syndr. 2011; 56(suppl 1): S33-S38.
97. Gowing L, Ali R, White JM: Buprenorphine for the management of opioid withdrawal. Cochrane Database Syst Rev. 2009; (3): CD002025.
98. Peppin JF, Coleman JJ, Kirsh KL: Issues and critiques of the forthcoming risk evaluation and mitigation strategy (REMS) for opioids in pain management. Issues Law Med. 2011; 27(2): 91-119.
99. Nicholson SC, Evanyo K, Salinas GD, et al: Extended-release/long-acting opioid REMS may fill the need for prescribers' appropriate use education. J Opioid Manag. 2012; 8(4): 212-216.
100. Slevin KA, Ashburn MA: Primary care physician opinion survey on FDA opioid risk evaluation and mitigation strategies. J Opioid Manag. 2011; 7(2): 109-115.
101. Kuroyanagi T, Ishii M: Declaration of Helsinki Expert Conference on the Ethics of Placebo Control in Clinical Trials - comments on the "reasonable availability" approach. Japanese Medical Association Journal. 2011; 54(6): 346-350.